Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study of TSR-022 Monotherapy or in Combination with TSR-042 in Patients with Colorectal Cancer and Post-PD-1 Non-Small Cell Lung Cancer and Melanoma

Next Previous
Trial Profile

A Phase 1, Open-Label Study of TSR-022 Monotherapy or in Combination with TSR-042 in Patients with Colorectal Cancer and Post-PD-1 Non-Small Cell Lung Cancer and Melanoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms AMBER

Most Recent Events

  • 09 Nov 2018 According to a TESARO media release, the monotherapy and combination dose-escalation parts of the study are complete.
  • 09 Nov 2018 According to a TESARO media release, additional data from this study are expected in 2019.
  • 09 Nov 2018 According to a TESARO media release, initial data from this study were presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference in Washington, D.C.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top